Geography and season are not always neutral in clinical trials
COVARIS helps pharmaceutical and biotech sponsors and CROs screen planned trial countries, regions and enrollment windows for disease-relevant environmental instability before protocol lock
Trial countries and regions are often selected for commercial, operational and recruitment reasons. Environmental stability across the planned footprint is less often assessed systematically, even though it can matter for exposure adequacy, endpoint variability and study robustness. COVARIS screens this variation and makes it decision-relevant before the protocol is locked.
Who we work with
COVARIS works with pharmaceutical and biotech sponsors and CROs at the planning stage of late phase 2 and phase 3 trials, particularly where planned countries, regions or enrollment windows may introduce seasonal or environmental instability.
COVARIS does not claim to predict outcomes or prove causal effects. Instead, it helps make environmental context explicit, comparable and relevant to pre-protocol decisions.
Why this matters
Environmental conditions across a planned trial footprint are not always stable, even or neutral in relation to disease activity, exposure adequacy or endpoint measurement.
COVARIS helps sponsors distinguish expected real-world heterogeneity from environmental variation that may be excessive, avoidable or worth documenting before it becomes a protocol problem.
Grounded in ICH E5 and ICH E17
COVARIS builds on the planning logic of ICH E5 and ICH E17, where intrinsic and extrinsic factors are recognized as relevant to how clinical data are generated, interpreted and applied across regions.
ICH E17 specifically calls for regional variability and the role of intrinsic and extrinsic factors to be carefully considered at the planning stage of multi-regional clinical trials. COVARIS focuses on one underdeveloped part of that question: environmental extrinsic factors.
What COVARIS does
COVARIS screens planned clinical trial countries, regions and enrollment windows using disease-relevant environmental variables selected during scoping.
The analysis can include environmental stability, regional variation, seasonal patterns and environmental instability across the planned trial footprint.
COVARIS is designed for use under realistic operational and commercial constraints. It supports earlier visibility and more explicit trial geography review before protocol lock.
What to expect
Initial conversation
A short discussion of indication, planned countries or regions, enrollment window and key trial-planning assumptions.
Scope definition
COVARIS identifies which environmental variables are relevant and defensible for the disease area, geography and study window.
Screening delivery
COVARIS screens the planned trial footprint for environmental stability, variation and contextual instability.
Readout
Findings are delivered as a sponsor-facing readout with implications for planning discussions before protocol lock.
How COVARIS works
COVARIS builds on a governed environmental data foundation that makes selected environmental variables comparable across countries, regions, seasons and study windows.
Variables are selected during scoping and only included when the disease rationale, data quality and trial-planning relevance are defensible.
How COVARIS can be applied
COVARIS applies the same methodological core in a small number of closely related ways.
Pre-protocol environmental screening
Screen planned trial countries, regions and enrollment windows for environmental variation that may be relevant before protocol lock.
Constrained redesign support
Explore whether moderate shifts in planned patient enrollment across countries and regions could produce a more stable trial footprint under realistic operational constraints.
Realized exposure and transferability context
In scoped cases, COVARIS can provide environmental exposure data matched to actual trial geographies, or compare trial context with a target country or region.
Illustrative cases
Global COPD clinical trial
A cumulative global case showing how environmental dispersion across a planned clinical trial geography can be assessed and reduced under realistic country and regional constraints.
IMMvent
A supporting constrained what-if case showing that a public clinical trial geography can be reconstructed and tested through environmental scenario logic.
Atopic dermatitis humidity context case
A disease-near case showing how humidity can be treated as a medically relevant environmental extrinsic factor in atopic dermatitis.
COPD therapy case
A transferability credibility case showing how COVARIS can identify both supportive and non-supportive contextual findings in a structured way.
Discuss a trial footprint
If you are working on late phase 2 or phase 3 planning, COVARIS can help assess whether planned countries, regions or enrollment windows introduce environmental instability worth considering before protocol lock.
COVARIS helps sponsors and CROs screen planned trial countries, regions and enrollment windows for disease-relevant environmental instability before protocol lock.
COVARIS does not predict outcomes or prove causal effects. It provides planning-stage environmental context intelligence for sponsor-led clinical trial decisions.
COVARIS ApS
2100 Copenhagen
Denmark
+45 25 30 30 28
CVR-no.: 46484673